Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis.
In a pilot study 12 patients with radically resected inguinal lymph node metastases from carcinoma of the penis and 5 patients with fixed inguinal nodes were treated with 12 weekly courses of vincristine, bleomycin and methotrexate (VBM). Only 1 of the 12 cases treated with adjuvant VBM relapsed after a median follow-up period of 42 months (range 18-102 months). Three partial responders to neoadjuvant VBM could have radical lymphadenectomy and they are alive disease-free 20, 27, 72 months after surgery. Two minimal responders could not have radical surgery and they died of the disease within one year.
Pizzocaro
G
G
Section of Urologic Oncology, Istituto Nazionale Tumori, Milano, Italy.
Piva
L
L
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000009:adverse effects / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D006801:Humans; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D010412:Penile Neoplasms / Q000188:drug therapy*; D010865:Pilot Projects; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
D001761:Bleomycin; D014750:Vincristine; D008727:Methotrexate